Navigation Links
Progentix Orthobiology B.V. Closes Series A Financing Round
Date:1/22/2008

BILTHOVEN, The Netherlands, January 22 /PRNewswire/ -- Progentix Orthobiology B.V. announced today the closure of its Series A financing Round. The round was led by BioGeneration Ventures.

Progentix Orthobiology B.V. was established in 2007 and develops a unique suite of osteoinductive material products for clinical application in bone regenerative surgery. Progentix bone graft material is based on surface structured ceramic biomaterial scaffolds that have the ability to attract growth factors and stems cells after implantation, which results in the induction of bone growth. These materials are not only superior to currently available synthetic ceramic bone grafts, but based on their bone healing and regeneration potential also directly compete with the gold standard of autologous bone, and the growth factors that are being used today and those under development. The Series A financing round will support further technology validation and the generation of clinical proof of principle.

Dr. Joost de Bruijn, CEO of Progentix Orthobiology said: "We are extremely pleased with the support of BioGeneration Ventures. This financing round will allow us to continue building value and lay the groundwork for the launch of our first products in the near future."

"We strongly believe in the high quality of the Progentix Orthobiology technology," says Edward van Wezel M.Sc., managing partner at BioGeneration Ventures BV. "This novel technology platform will address a real medical need in the area of bone grafts. The scientific team has an excellent track record in the development of biomaterials and tissue engineering." Dr. Clemens van Blitterswijk, professor in Tissue Regeneration at the University of Twente and former CEO of IsoTis N.V., and Edward van Wezel will join the board of directors of Progentix Orthobiology.

About Biogeneration Ventures BV

BioGeneration Ventures invests in Dutch Life Sciences companies. The team of BioGeneration is specialized in the evaluation of new technologies and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates with Forbion Capital Partners (http://www.forbion.com).

Contact:

Progentix Orthobiology B.V.

Prof. Dr. Joost de Bruijn

T: +31-30-2295234

E: info@progentix.com

W: http://www.progentix.com

BioGeneration Ventures B.V.

Edward van Wezel

T: +31-35-6993011

E: info@biogenerationventures.com

W: http://www.biogenerationventures.com


'/>"/>
SOURCE Progentix Orthobiology
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):